JPS584752A - カルボキシアミド誘導体及びその製造法 - Google Patents
カルボキシアミド誘導体及びその製造法Info
- Publication number
- JPS584752A JPS584752A JP57109097A JP10909782A JPS584752A JP S584752 A JPS584752 A JP S584752A JP 57109097 A JP57109097 A JP 57109097A JP 10909782 A JP10909782 A JP 10909782A JP S584752 A JPS584752 A JP S584752A
- Authority
- JP
- Japan
- Prior art keywords
- cyclopropane
- group
- hydrochloride
- alkyl group
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003169 central nervous system Anatomy 0.000 title claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 10
- 125000005843 halogen group Chemical group 0.000 claims abstract description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 6
- 150000007522 mineralic acids Chemical class 0.000 claims abstract description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000003277 amino group Chemical group 0.000 claims abstract 4
- 125000003118 aryl group Chemical group 0.000 claims abstract 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 3
- 150000007524 organic acids Chemical class 0.000 claims abstract 3
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 2
- 125000005842 heteroatom Chemical group 0.000 claims abstract 2
- 235000005985 organic acids Nutrition 0.000 claims abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 54
- 150000001875 compounds Chemical class 0.000 claims description 16
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 10
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 7
- 239000001294 propane Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229910052736 halogen Chemical group 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract description 3
- 229910052801 chlorine Inorganic materials 0.000 abstract description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 13
- 239000013078 crystal Substances 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- HIJXSRHMNAUOKJ-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-phenylcyclopropane-1-carboxamide Chemical compound CN(C)CC1CC1(C(N)=O)C1=CC=CC=C1 HIJXSRHMNAUOKJ-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- MHLMRBVCMNDOCW-UHFFFAOYSA-N acetic acid;butan-1-ol;hydrate Chemical compound O.CC(O)=O.CCCCO MHLMRBVCMNDOCW-UHFFFAOYSA-N 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- UPWDDVVPPMNVAU-UHFFFAOYSA-N C(=O)=C1C(C1)CN Chemical compound C(=O)=C1C(C1)CN UPWDDVVPPMNVAU-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- -1 organic acid salt Chemical class 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
- KZVMSZSVPCWNCC-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-n,n-dimethylcyclopropane-1-carboxamide Chemical compound CN(C)CC1CC1C(=O)N(C)C KZVMSZSVPCWNCC-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical class CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- ZKPUPHSBFMNFHO-UHFFFAOYSA-N [ClH]1C=CC=C1 Chemical compound [ClH]1C=CC=C1 ZKPUPHSBFMNFHO-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- OJHAHQJRQIOCFK-UHFFFAOYSA-N azane;chloroform;methanol Chemical compound N.OC.ClC(Cl)Cl OJHAHQJRQIOCFK-UHFFFAOYSA-N 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8112312A FR2508035A1 (fr) | 1981-06-23 | 1981-06-23 | Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
| FR8112312 | 1981-06-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS584752A true JPS584752A (ja) | 1983-01-11 |
| JPS6323186B2 JPS6323186B2 (OSRAM) | 1988-05-16 |
Family
ID=9259785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57109097A Granted JPS584752A (ja) | 1981-06-23 | 1982-06-23 | カルボキシアミド誘導体及びその製造法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4478836A (OSRAM) |
| EP (1) | EP0068999B1 (OSRAM) |
| JP (1) | JPS584752A (OSRAM) |
| AT (1) | ATE13422T1 (OSRAM) |
| AU (1) | AU550774B2 (OSRAM) |
| CA (1) | CA1202639A (OSRAM) |
| DE (1) | DE3263734D1 (OSRAM) |
| ES (1) | ES8303293A1 (OSRAM) |
| FR (1) | FR2508035A1 (OSRAM) |
| LU (1) | LU90410I2 (OSRAM) |
| ZA (1) | ZA824453B (OSRAM) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995022521A1 (en) * | 1994-02-22 | 1995-08-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Aminoalkylcyclopropane derivative |
| WO2006132307A1 (ja) * | 2005-06-10 | 2006-12-14 | Pierre Fabre Medicament S.A. | 安定化されたミルナシプラン製剤 |
| JP2007502253A (ja) * | 2003-08-15 | 2007-02-08 | ハー・ルンドベック・アクチエゼルスカベット | Ｎｋ３受容体アンタゴニストとしてのシクロプロピル誘導体 |
| WO2007086493A1 (ja) * | 2006-01-27 | 2007-08-02 | Asahi Kasei Pharma Corporation | 経鼻投与用薬剤 |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2581059B1 (fr) * | 1985-04-25 | 1988-04-22 | Pf Medicament | Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z) |
| FR2581060B1 (fr) * | 1985-04-25 | 1988-07-01 | Pf Medicament | Procede industriel d'obtention du midalcipran |
| CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
| EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| DK0759299T3 (da) * | 1995-08-16 | 2000-08-07 | Lilly Co Eli | Potensering af serotoninrespons |
| FR2752732B1 (fr) * | 1996-08-28 | 1998-11-20 | Pf Medicament | Forme galenique a liberation prolongee de milnacipran |
| JP4494015B2 (ja) * | 2001-10-12 | 2010-06-30 | アゼヴァン ファーマスーティカルズ，インコーポレイテッド | β−ラクタミル・バソプレッシンＶ１ａ拮抗剤 |
| US6635675B2 (en) * | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
| US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| US20040034101A1 (en) * | 2001-11-05 | 2004-02-19 | Cypress Bioscience, Inc. | Treatment and prevention of depression secondary to pain (DSP) |
| US20030232805A1 (en) * | 2002-04-24 | 2003-12-18 | Cypress Bioscience, Inc. | Prevention and treatment of functional somatic disorders, including stress-related disorders |
| US7038085B2 (en) * | 2002-10-25 | 2006-05-02 | Collegium Pharmaceutical, Inc. | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
| FR2851163B1 (fr) | 2003-02-14 | 2007-04-27 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament | |
| SI1601349T1 (sl) | 2003-02-14 | 2008-10-31 | Pf Medicament | Uporaba enantiomera milnaciprana za pripravo zdravila |
| EP1620083A2 (en) * | 2003-04-18 | 2006-02-01 | Pharmacia & Upjohn Company LLC | Combination therapies |
| NZ544935A (en) | 2003-08-15 | 2009-08-28 | Lundbeck & Co As H | Cyclopropyl derivatives as NK3 receptor antagonists |
| CA2548917C (en) | 2003-12-11 | 2014-09-23 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| EP1737473A4 (en) * | 2004-04-19 | 2009-08-26 | Noven Therapeutics Llc | COMBINATIONS OF LITHIUM AND USES THEREOF |
| JP4418717B2 (ja) * | 2004-06-24 | 2010-02-24 | 住友化学株式会社 | （ｚ）−１−フェニル−１−ジエチルアミノカルボニル−２−アミノメチルシクロプロパン塩酸塩の製造方法 |
| WO2006102308A2 (en) | 2005-03-22 | 2006-09-28 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl vasopressin v1b antagonists |
| AU2006239922A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists |
| TW200719886A (en) * | 2005-04-22 | 2007-06-01 | Wyeth Corp | Dihydrobenzofuran derivatives and uses thereof |
| BRPI0608475A2 (pt) * | 2005-04-22 | 2010-01-05 | Wyeth Corp | derivados de diidrobenzofurano e usos dos mesmos |
| SG163588A1 (en) | 2005-07-08 | 2010-08-30 | Braincells Inc | Methods for identifying agents and conditions that modulate neurogenesis |
| JP5328349B2 (ja) * | 2005-07-19 | 2013-10-30 | アゼヴァン ファーマスーティカルズ，インコーポレイテッド | ベータ−ラクタミルフェニルアラニン、システイン、およびセリン・バソプレッシン拮抗剤 |
| US20090203750A1 (en) * | 2005-08-24 | 2009-08-13 | Alan Kozikowski | 5-HT2C Receptor Agonists as Anorectic Agents |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20080319083A1 (en) * | 2006-01-27 | 2008-12-25 | Asahi Kasei Pharma Corporation | Medicine for transnasal administration |
| FR2912057B1 (fr) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| TW200806300A (en) * | 2006-03-24 | 2008-02-01 | Wyeth Corp | New therapeutic combinations for the treatment of depression |
| MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
| JP2010502722A (ja) | 2006-09-08 | 2010-01-28 | ブレインセルス，インコーポレイティド | ４−アシルアミノピリジン誘導体を含む組み合わせ |
| US20100016274A1 (en) * | 2006-09-14 | 2010-01-21 | Koppel Gary A | Beta-lactam cannabinoid receptor modulators |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20080167363A1 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc | Modulation of Neurogenesis By Melatoninergic Agents |
| AU2008204800A1 (en) * | 2007-01-11 | 2008-07-17 | Braincells, Inc. | Modulation of neurogenesis with use of modafinil |
| EP2114868A2 (en) * | 2007-02-28 | 2009-11-11 | Ranbaxy Laboratories Limited | Novel polymorphic forms of milnacipran hydrochloride |
| US20090048233A1 (en) * | 2007-08-16 | 2009-02-19 | Cypress Biosciences, Inc. | Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination |
| US20090069431A1 (en) * | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched milnacipran |
| EP2288345B1 (en) | 2008-04-18 | 2015-06-10 | University College Dublin National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| WO2010021681A2 (en) * | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| WO2010036773A1 (en) * | 2008-09-24 | 2010-04-01 | Concert Pharmaceuticals, Inc. | Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives |
| FR2941454B1 (fr) | 2009-01-29 | 2011-04-01 | Pf Medicament | Proced de synthese du (1s,2r)-milnacipran |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20100274050A1 (en) * | 2009-04-23 | 2010-10-28 | Glenmark Generics Limited | Solid milnacipran and process for the preparation of the same |
| US20100286260A1 (en) * | 2009-05-05 | 2010-11-11 | Forest Laboratories Holdings Ltd. | Milnacipran formulations |
| WO2011016057A2 (en) | 2009-08-05 | 2011-02-10 | Lupin Limited | Controlled release pharmaceutical compositions of milnacipran |
| EP2496079A4 (en) * | 2009-11-06 | 2014-05-14 | Pierre Fabre Médicament Sas | NOVEL (1S, 2R) -2- (AMINOMETHYL) -N, N-DIETHYL-1-PHENYLCYCLOPROPANECARBOXAMIDE CRYSTALLINE FORMS |
| WO2011092065A1 (en) | 2010-01-29 | 2011-08-04 | Nicox S.A. | Nitric oxide releasing compounds for the treatment of neurophatic pain |
| JP2013535425A (ja) | 2010-07-01 | 2013-09-12 | アゼヴァン ファーマシューティカルズ，インコーポレイテッド | 心的外傷後ストレス障害を治療する方法 |
| US8916194B2 (en) | 2010-08-30 | 2014-12-23 | Lupin Limited | Controlled release pharmaceutical compositions of milnacipran |
| US20120289744A1 (en) | 2010-11-03 | 2012-11-15 | Arch Pharmalabs Limited | Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts |
| WO2012145234A2 (en) * | 2011-04-21 | 2012-10-26 | Emory University | Cyclopropyl derivatives and methods of use |
| WO2014009767A1 (en) | 2012-07-07 | 2014-01-16 | Micro Labs Limited | An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers and salts |
| WO2014203277A2 (en) * | 2013-06-19 | 2014-12-24 | Msn Laboratories Private Limited | Process for the preparation of (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanearboxamide hydrochloride |
| WO2015044962A1 (en) | 2013-09-30 | 2015-04-02 | Cadila Healthcare Limited | Amorphous form of levomilnacipran hydrochloride and hydrates thereof |
| JP7255967B2 (ja) | 2014-03-28 | 2023-04-11 | アゼヴァン ファーマスーティカルズ，インコーポレイテッド | 神経変性疾患を治療するための組成物および方法 |
| CN111295373B (zh) | 2017-09-15 | 2024-12-10 | 阿泽凡药物公司 | 用于治疗脑损伤的组合物和方法 |
| KR20220049526A (ko) | 2019-07-19 | 2022-04-21 | 바이오엑셀 테라퓨틱스 인코포레이티드 | 비-진정성 덱스메데토미딘 치료 양생법 |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA619080A (en) * | 1961-04-25 | The Upjohn Company | N-SUBSTITUTED-.alpha.-(TERTIARY-AMINOALKYL)-.alpha.-PHENYLACETAMIDES | |
| CA570688A (en) * | 1959-02-17 | E. Speeter Merrill | Antispasmodic substituted amines | |
| GB1415541A (en) * | 1972-11-30 | 1975-11-26 | Hexachimie | 1-amino-methyl-2,2-diarylcyclopropanecarboxamide |
-
1981
- 1981-06-23 FR FR8112312A patent/FR2508035A1/fr active Granted
-
1982
- 1982-06-04 ES ES512842A patent/ES8303293A1/es not_active Expired
- 1982-06-21 AT AT82401129T patent/ATE13422T1/de active
- 1982-06-21 DE DE8282401129T patent/DE3263734D1/de not_active Expired
- 1982-06-21 EP EP82401129A patent/EP0068999B1/fr not_active Expired
- 1982-06-22 AU AU85086/82A patent/AU550774B2/en not_active Expired
- 1982-06-22 CA CA000405651A patent/CA1202639A/fr not_active Expired
- 1982-06-22 US US06/390,810 patent/US4478836A/en not_active Expired - Lifetime
- 1982-06-23 JP JP57109097A patent/JPS584752A/ja active Granted
- 1982-06-23 ZA ZA824453A patent/ZA824453B/xx unknown
-
1999
- 1999-06-30 LU LU90410C patent/LU90410I2/fr unknown
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995022521A1 (en) * | 1994-02-22 | 1995-08-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Aminoalkylcyclopropane derivative |
| JP2007502253A (ja) * | 2003-08-15 | 2007-02-08 | ハー・ルンドベック・アクチエゼルスカベット | Ｎｋ３受容体アンタゴニストとしてのシクロプロピル誘導体 |
| WO2006132307A1 (ja) * | 2005-06-10 | 2006-12-14 | Pierre Fabre Medicament S.A. | 安定化されたミルナシプラン製剤 |
| US8309128B2 (en) | 2005-06-10 | 2012-11-13 | Pierre Fabre Medicament | Stabilized milnacipran formulation |
| WO2007086493A1 (ja) * | 2006-01-27 | 2007-08-02 | Asahi Kasei Pharma Corporation | 経鼻投与用薬剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2508035A1 (fr) | 1982-12-24 |
| EP0068999A1 (fr) | 1983-01-05 |
| US4478836A (en) | 1984-10-23 |
| EP0068999B1 (fr) | 1985-05-22 |
| CA1202639A (fr) | 1986-04-01 |
| FR2508035B1 (OSRAM) | 1984-06-29 |
| AU550774B2 (en) | 1986-04-10 |
| ES512842A0 (es) | 1983-03-01 |
| DE3263734D1 (en) | 1985-06-27 |
| LU90410I2 (fr) | 1999-08-31 |
| ES8303293A1 (es) | 1983-03-01 |
| AU8508682A (en) | 1983-01-06 |
| ZA824453B (en) | 1983-04-27 |
| ATE13422T1 (de) | 1985-06-15 |
| JPS6323186B2 (OSRAM) | 1988-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS584752A (ja) | カルボキシアミド誘導体及びその製造法 | |
| AU2014239995B2 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| ES2258331T3 (es) | Compuestos heterociclicos y procedimientos de tratamiento de insuficiencia cardiaca y otros trastornos. | |
| JP3210771B2 (ja) | アリールアセタマイド | |
| BG64891B1 (bg) | Тиенилазолилалкоксиетанамини, тяхното получаване и приложението им като лекарствени средства | |
| JP2004503549A (ja) | 生体等配電子性ベンズアミド誘導体およびそのアポｂ−１００分泌阻害剤としての使用 | |
| KR100447033B1 (ko) | 신규한2-나프타미드유도체와이의치료제로서의사용 | |
| JPS60123485A (ja) | インド−ル−３−カルボキサミド誘導体 | |
| SU1241986A3 (ru) | Способ получени производных бензамида,их гидрохлоридов или оптических изомеров | |
| JP2025131661A (ja) | ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態 | |
| US4431663A (en) | Treatment of psychosis with meta-sulfonamido-benzamide derivatives | |
| DE60316683T2 (de) | Phenylcyclohexylpropanolaminderivate, deren herstellung und therapeutsche anwendung | |
| JPWO2009041559A1 (ja) | インダゾールアクリル酸アミド化合物 | |
| JPS5955878A (ja) | 新規なフエニルピペラジン誘導体 | |
| JPWO2008029924A1 (ja) | 環状アミノアルキルカルボキサミド誘導体 | |
| JPH0291052A (ja) | 置換アミン類 | |
| BRPI0613987A2 (pt) | derivados de benzilpiperazina e seu uso médico | |
| JPS6230762A (ja) | 新規５−オキソ−１−イミダゾリジンアセトアミド誘導体 | |
| TW202245746A (zh) | Ｎ－（（ｒ）－２，３－二羥基丙氧基）—３，４—二氟—２—（２—氟—４—碘—苯基胺基)—苯甲醯胺之基本上純的形式ｉｖ之組合物及其用途 | |
| DE1931240A1 (de) | Aminoalkancarbonsaeuren | |
| CN108863892A (zh) | 一种含酰胺结构的没食子酸甲酯类似物及应用 | |
| JP5442711B2 (ja) | Ｈｄｌ−コレステロール上昇剤としての２−トリフルオロメチルニコチンアミド誘導体 | |
| JP2001511798A (ja) | オキシド−スクアレンシクラーゼ抑制剤として有用な複素環化合物 | |
| JP5856971B2 (ja) | 結晶性ｃｄｃ７阻害剤塩 | |
| JP2011102241A (ja) | 新規１−アミノカルボニルピペリジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080516 Year of fee payment: 20 |